Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 61, Issue 3, 2003, Pages 167-173

  Lindsay, J R ^a   McKillop, A M ^b   Mooney, M H ^b   O'Harte, F P M ^b   Flatt, P R ^b   Bell, P M ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Glucose tolerance; Glycated insulin; Nateglinide; Type 2 diabetes

Indexed keywords

C PEPTIDE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; NATEGLINIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIABETIC DIET; DIET RESTRICTION; DRUG EFFECT; DRUG SCREENING; FEMALE; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RADIOIMMUNOASSAY; RANDOMIZATION; SINGLE BLIND PROCEDURE;

EID: 0043264265     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(03)00107-4     Document Type: Article

References (29)

1. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
2. Pratley R.E., Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia. 44:2001;929-945.
3. Glucose tolerance and mortality: comparison of WHO and American diabetes association diagnostic criteria. Lancet. 354:1999;617-621.
4. Pfeifer M.A., Halter J.B., Porte D.J. Insulin secretion in diabetes mellitus. Am. J. Med. 70:1981;579-588.
5. Pratley R.E., Foley J.E., Dunning B.E. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr. Pharm. Des. 7:2001;1375-1397. Malaisse W.J. Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies. Eur. J. Clin. Invest. 29:(Suppl. 2):1999;21-29.
6. Malaisse W.J. Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies. Eur. J. Clin. Invest. 29:(Suppl. 2):1999;21-29.
7. Horton E.S., Clinkingbeard C., Gatlin M., Foley J., Mallows S., Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 23:2000;1660-1665.
8. Sato Y., Nishikawa M., Shinkai H., Sukegawa E. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res. Clin. Pract. 12:1991;53-59.
9. Ikenoue T., Akiyoshi M., Fujitani S., Okazaki K., Kondo N., Maki T. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). Br. J. Pharmacol. 120:1997;137-145.
10. Akiyoshi M., Kakei M., Nakazaki M., Tanaka H. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic beta-cells. Am. J. Physiol. 268:1995;E185-E193.
11. Karara A.H., Dunning B.E., McLeod J.F. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J. Clin. Pharmacol. 39:1999;172-179.
12. Abdel-Wahab Y.H., O'Harte F.P., Ratcliff H., McClenaghan N.H., Barnett C.R., Flatt P.R. Glycation of insulin in the islets of Langerhans of normal and diabetic animals. Diabetes. 45:1996;1489-1496.
13. McKillop A.M., McCluskey J.T., Boyd A.C., Mooney M.H., Flatt P.R., O'Harte F.P. Production and characterization of specific antibodies for evaluation of glycated insulin in plasma and biological tissues. J. Endocrinol. 167:2000;153-163.
14. McKillop A.M., Mooney M.H., Harriott P., Flatt P.R., O'Harte F.P. Evaluation of glycated insulin in diabetic animals using immunocytochemistry and radioimmunoassay. Biochem. Biophys. Res. Commun. 286:2001;524-528.
15. Abdel-Wahab Y.H., O'Harte F.P., Barnett C.R., Flatt P.R. Characterization of insulin glycation in insulin-secreting cells maintained in tissue culture. J. Endocrinol. 152:1997;59-67.
16. Boyd A.C., Abdel-Wahab Y.H., McKillop A.M., McNulty H., Barnett C.R., O'Harte F.P., Flatt P.R. Impaired ability of glycated insulin to regulate plasma glucose and stimulate glucose transport and metabolism in mouse abdominal muscle. Biochim. Biophys. Acta. 1523:2000;128-134.
17. Hunter S.J., Boyd A.C., O'Harte F.P.M., McKillop A.M., Wiggam M.I., Mooney M.H., McCluskey J.T., Lindsay J.R., Ennis C.N., Gamble R., Sheridan B., Barnett C.R., McNulty H., Bell P.M., Flatt P.R. Demonstration of glycated insulin in human diabetic plasma and decreased biological activity assessed by euglycemic hyperinsulinemic clamp technique in man. Diabetes. 52:2003;492-498.
18. Abdel-Wahab Y.H., O'Harte F.P., Boyd A.C., Barnett C.R., Flatt P.R. Glycation of insulin results in reduced biological activity in mice. Acta Diabetol. 34:1997;265-270.
19. Lindsay J.R., McKillop A.M., Mooney M.H., O'Harte F.P.M., Bell P.R., Flatt P.R. Demonstration of elevated concentrations of circulating glycated insulin in human type 2 diabetes using a novel and specific radioimmunoassay. Diabetologia. 46:2003;475-478.
20. Lindsay J.R., McKillop A.M., Mooney M.H., Flatt P.R., Bell P.M., O'Harte F.P.M. Meal-induced 24 h profile of circulating glycated insulin in type 2 diabetic subjects measured by a novel radioimmunoassay. Metabolism. 52:2003;631-635.
21. Salacinski P.R., McLean C., Sykes J.E., Clement-Jones V.V., Lowry P.J. Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenyl glycoluril (iodogen). Anal. Biochem. 117:1981;136-146.
22. Stevens J.F. Determination of glucose by an automatic analyzer. Clin. Chim. Acta. 32:1971;199-201.
23. Fossati P., Ponti M., Passoni G., Tarenghi G., Melzi D.E., Prencipe L. A step forward in enzymatic measurement of creatinine. Clin. Chem. 40:1994;130-137.
24. Flatt P.R., Abdel-Wahab Y.H., Boyd A.C., Barnett C.R., O'Harte F.P. Pancreatic B-cell dysfunction and glucose toxicity in non-insulin-dependent diabetes. Proc. Nutr. Soc. 56:1997;243-262.
25. Keilson L., Mather S., Walter Y.H., Subramanian S., McLeod J.F. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 85:2000;1081-1086.
26. Ahren B., Holst J.J. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes. 50:2001;1030-1038.
27. Ahren B. Autonomic regulation of islet hormone secretion - implications for health and disease. Diabetologia. 43:2000;393-410.
28. Parsons T.D., Coorssen J.R., Horstmann H., Almers W. Docked granules, the exocytic burst, and the need for ATP hydrolysis in endocrine cells. Neuron. 15:1995;1085-1096.
29. Parsons T.D., Coorssen J.R., Horstmann H., Lee A.K., Tse F.W., Almers W. The last seconds in the life of a secretory vesicle. Cold Spring Harb. Symp. Quant. Biol. 60:1995;389-396.